INTRODUCTION
Several methods have been reported to detect rheumatoid factor (RF) ' in, or associated with, lymphoid cells.
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These have included staining with fluorescent-labeled aggregated human IgG (1) (2) (3) (4) , mixed agglutination in fixed tissues (5) , and production of rosettes with sensitized erythrocytes mixed with lymphocytes (6, 7) . None of these procedures, however, assesses RF production. Culture of mixed cell suspensions in the presence of radio-labeled amino acids (8) has indicated RF production by yielding radiolabeled RF, but the numbers or types of cells involved in the production was not revealed by this method.
Some of our recent observations brought forth the possibility that we could detect RF production by single cells. We have shown (9) that: (a) IgM RF fixes and activates guinea pig and human complement via the classical complement pathway; (b) IgM RF prepares sheep erythrocytes coated with reduced and alkylated rabbit IgG hemolysin for lysis by complement; and (c) the percentage of hemolysis is directly proportional to RF agglutination titer.
These observations led us to attempt to use the direct hemolytic plaque assay described by Jerne et al. (10) The presence of RF-PFC in the peripheral blood correlates with active, exacerbating, or aggressive disease.
METHODS
Subjects. The patient populations studied included an initial group of 72 patients with seropositive rheumatoid arthritis (RA) randomly selected from our clinics, 14 with seronegative RA, 14 non-RA patients with a variety of rheumatic diseases, and 24 normal individuals who were RF negative. The patients with RA were all classical or definite RA according to the American Rheumatism Association criteria (11) . A second series included 16 seropositive RA patients most of whom were on a drug trial with Naprosyn (Syntex Laboratories, Inc., Palo Alto, Calif.). They were selected as a group because they had generally mild-to-moderate disease and were not on corticosteroids. A third group consisted of 18 patients selected for study because of the clinical impression of more active or aggressive disease in them.
Most patients were examined in our ambulatory clinics. Some were hospitalized in our Clinical Research Center for more prolonged and intensive investigations. The patients on the drug study were followed in the ambulatory facility of our Clinical Research Center, where more detailed clinical observation could be made than in our regular clinics. All patients were fully informed of the nature of the studies undertaken and gave willing consent.
Clinical characteristics. RA patients with any evidence of generalized vasculitis were assigned to the vasculitis group. Manifestations of vasculitis ranged from nail fold infarcts to mononeuritis multiplex and typical vasculitic cutaneous ulcerations. In this report no distinction is made between patients with minimal and severe vasculitis.
Patients were regarded as having an acute flare if they had acute synovitis of less than a 2-wk duration. A joint already exhibiting synovial hypertrophy and effusion was considered the site of recrudescent acute synovitis only in the event of sudden increase in joint volume, tenderness, pain, erythema, or heat. Patients with two or more acutely inflamed joints were considered to have polyarticular synovitis.
All patients who were seen in our Clinical Research Center were evaluated serially with the American Rheumatism Association Database (12) as the form of clinical assessment.
Preparation of lymphocytes. Lymphocytes from peripheral blood and synovial fluid were generally purified by differential centrifugation on Ficoll-Hypaque (13), or occasionally by dextran sedimentation with iron lysine (14, 15) . Preparations from peripheral blood consisted of cells appearing morphologically greater than 92% viable small lymphocytes. Lesser degrees of purity of the lymphocytes were encountered with some preparations from synovial effusions.
Bone marrow was aspirated from the posterior iliac crest, or in some instances from the sternum, 5 ml being taken into a plastic syringe containing 10 (9) .
Measurement of RF activity. The RF activity of sera and synovial effusions was measured by the slide latex fixation test (LFT, RA test, Hyland Laboratories, Los Angeles, Calif.) and by the sensitized sheep cell agglutination tests (SCAT) (16) . The latter was carried out by settling patterns in microtiter plates.
Soutrce of comnplenent. Lyophilized guinea pig serum (Hyland Laboratories) was reconstituted with the diluent provided. For some experiments natural antibody to SRC was absorbed by repeated incubation at 0'C with packed SRC as reportedl previously (9) . PFC assay for RF proditction. 0.5 ml of 0.5% agarose at 44'C (agarose A-37 Indubiose R, L'Industrie Biologique, Frangaise, S. A., Gennevilliers, France) was mixed with 0.1 ml of lymphocyte suspension containing 1-5 x 106 lymphocytes and 0.05 ml of a 6.7% suspension of SRC coated with reduced and alkylated rabbit IgG hemolysin. The mixture was then promptly poured onto precoated microscope slides. The slides were incubated at 37'C for 90 min in a moist chamber, then immersed in a 1: 10 dilution of guinea pig complement and incubated an additional 90 min at 37' C. Preabsorption of the guinea pig complement to remove natural antibody to SRC did not prove to be necessary since there was no significant background lysis of the unsensitized SRC controls. RF-PFC were enumerated under magnification. Similar cell suspensions employing nonsensitized erythrocytes were examined as controls to detect any lymphocytes synthesizing natural antibody to SRC.2 Control PFC were subtracted from PFC with sensitized erythrocytes and the results were expressed as RF-PFC/106 lymphocytes. Generally, four replicate determinations were made for each preparation.
Metabolic inhibition. Puromycin, cycloheximide, and dibutyryl cyclic AMP were obtained from Calbiochem, San Diego, Calif. 8-bromo cyclic GMP was obtained from Sigma Chemical Co., St. Louis, Mo. Vinblastine was obtained from Eli Lilly and Co., Indianapolis, Ind. Inhibitors were added to 0.5-ml aliquots of melted agar (zide sitpra) in 10-,ul volumes just before the lymphocytes and sensitized erythrocytes. Thereafter, the preparations were poured and subsequently handled in the usual fashion.
Preparation of data. Statistical comparisons were made by the Student's t test on log transformation. The exponentiated mean+±SEM is used throughout the paper. Immunological studies. The RF-PFC were complement dependent, since leaving complement out of the assay resulted in no plaques, and introduction of complement earlier during the assay, i.e., at the time of mixing of the cells with the agarose, resulted in earlier appearance of the plaques.
RESULTS
The specificity of the RF-PFC assay has been investigated. Since rabbit rather than human IgG hemolysin was used to sensitize the sheep cells in the assay, the question had to be answered whetlher the PFC were due to heterospecific rather than autospecific antibodies. To answer this question, inhibition studies were carried out, in which human, rabbit, or bovine IgG was incorporated in varying doses in the agar (Fig. 1) . Three patients' cells were examined (Ta, So, and Ra). Both bone marrow (BM) and peripheral blood lymphocytes (PBL) were used as sources for the RF-PFC. Human IgG regularly provided better inhibition than rabbit IgG. Bovine IgG was least effective. Therefore, the RF (anti-IgG) detected in the PFC assay can be properly regarded as autoantibody. There was no doubt about the specificity of the inhibition of RF-PFC, since the RF-PFC were not inhibited in high concentrations of other serum proteins. For instance, there was no inhibition in 10% FBS.
A surprise was that human IgG actually had greater efficacy than rabbit IgG in the RF-PFC inhibition, since the common experience in assaying the peripheral blood serum for RF with the SCAT has been that rabbit IgG is a better inhibitor than human IgG (17, 18) . The SCAT assay, like the RF-PFC assay, used SRC sensitized with rabbit IgG as the indicator cell. Thus the RF at its source (the RF-PFC assay) appeared to be different from RF in the peripheral serum (the SCAT assay), as will be discussed later.
To rule out that the three patients we studied were atypical, we performed inhibition assays on the SCAT reactions of the RF in these patients' sera taken at the time of the RF-PFC assays. The results are shown in Table I . The peripheral blood serum RF activities were inhibited best by rabbit IgG, less well by human IgG, and little or none by bovine IgG, just as lhad been described for RF in the serum previously (17, 18) .
The RF-PFC detected in our assay have been of the direct variety and therefore are assumed to represent IgM complement-fixing RF (10) . Attempts have been made to detect other varieties of RF by indirect means. We have added an antihuman IgG serum along with complement at the second incubation step in the assay (10) in the attempt to detect IgG RF. This has generally not yielded additional PFC and sometimes has inhibited because of the IgG present in the antiserum. Antihuman IgM antibody has been added in the attempt to detect noncomplement-fixing IgM RF-PFC, but no such PFC have been found.
Since our assay detects RF-PFC only by the crossreaction of the RF with rabbit IgG, attempts have been made to develop a cell coated with human IgG that can be used in the assay. The Ripley anti-CD antibody (19) These observations have been taken to mean: (a) only a minority of the RF-PFC have enough stored RF for plaque formation in the absence of continued protein synthesis; (b) the cyclic nucleotides probably do not modulate significantly the synthesis or release of the RF; and (c) the release depends upon intact microtubular or membrane structures.
During the course of these experiments, attempts were made to use increasing numbers of lymphocytes in the agar to increase the number of RF-PFC detected. It was noted that at cell concentrations higher than 3 X 106/slide, a corresponding increase in the number of RF-PFC was not seen. Rather, varying degrees of inhibition were found (Fig. 4) . When full tissue culture media were used in the agar instead of the usual balanced salt solution (BSS) (21) , however, the expected increment of RF-PFC with increased numbers of cells plaqued did occur (Fig. 5) . The inhibition seen in BSS alone (Fig. 4) Clinical observations. Table II shows our findings on RF-PFC in our first series of RA patients, including both those who were seropositive and those who were seronegative for RF in the serum. Cells from blood, synovial fluid, and BM were examined. 32 of 102 preparations of blood lymphocytes from 21 of 67 patients were positive with a range of 1-18 PFC/106 lymphocytes. In this first series we noted that RF-PFC were found especially in two circumstances; when the patients had acute exacerbations of polyarticular synovitis, or when they had generalized vasculitis.
19 synovial fluid lymphocyte preparations were examined, of which 4 were positive with a range of 3-14 PFC/10' lymphocytes. RF-PFC were found only in effusions from joints that were the sites of acute synovitis. Joints that were the sites of chronic indolent disease were negative, regardless of the duration of the svnovitis or the degree of synovial hypertrophy.
Eight BM preparations were examined. Four patients gave positive cells with a range of 2-22 RF-PFC/106 nucleated cells. Two of the four positive BM specimens were from patients who did not have RF-PFC in their peripheral bloods. In Table III On a number of occasions we examined the blood simultaneously with the BM or joint fluid cells for RF-PFC. As can be seen in Table IV , in all instances the BM had many more RF-PFC/106 lymphocytes than did the simultaneous peripheral blood. The synovial fluid lymphocytes sometimes had more RF-PFC. We have taken this to mean that the BM is a source of RF-PFC. The synovial tissues may also be a source, although the inflammation in the joints may conceivably lead to local sinkhole effects which concentrate RF-PFC in the area.
The relation of RF-PFC to severity of disease was investigated in two further series of patients with seropositive RA. The one (second series in Tables V and  VI) was a group with mild-to-moderate disease, most of whom were on a drug trial with aspirin, indomethacin, and Naprosyn, and none of whom were on corticosteroids. The other (third series) was a group of patients preselected over a 5-mo period for RF-PFC determinations because of a clinical impression of there being such active, aggressive, or exacerbating disease in them that there was high likelihood that their peripheral blood leukocytes would be positive. The tests on the bloods of these latter series were compared with those found among the patients with seropositive RA from our initial series (Table II) . The seropositive RA patients in our initial survey exhibited RF-PFC in their peripheral bloods in 22/67 (33%) of patients (Table V) . Most of these had fewer than 5 RF-PFC/106 lymphocytes. The group of patients selected to have mild-to-moderate disease showed almost identical findings. The group selected because of more active and aggressive disease, however, had RF-PFC in 10/18 (56%) and in the majority of positives there were more than 5 RF-PFC/10' lymphocytes. When patients with clinically diagnosable generalized vasculitis were selected from the three groups and scored as a separate series, it was noted (last column) that all were positive for RF-PFC. Further evaluation of these three series was carried out in an attempt to better define the clinical parameters that might correlate with presence of RF-PFC. In the second series, which was being followed closely in our Clinical Research Center, the commonly used indicators of disease activity such as number of painful joints, number of hot or swollen joints, hemoglobin and serum albumin levels, and hours of morning stiffness could be evaluated. None of these individually gave positive correlations with RF-PFC. This sort of detailed evaluation could not be made in the first or third series, since these latter groups were not being followed clinically by us, but by cooperating private physicians.
The charts of all three series, however, were evaluated retrospectively for other laboratory data collected simultaneously with the RF-PFC determinations, for ages of patients, and for drug therapy. The results are shown in Table VI . The most striking correlation with RF-PFC in the blood was a markedly elevated erythrocyte sedimentation rate. Very high titers of serum RF and treatment with corticosteroids also correlated with RF-PFC in the summated series, but not reproducibly so in the individual series. There was a tendency for RF-PFC to be found in older patients in all three groups, but at no point did this tendency reach statistical significance.
Serial studies of RF-PFC in the peripheral blood have been carried out in a number of patients. In almost all of these the RF-PFC were assessed for the first time during an exacerbation of disease. Repeatedly we have noted disappearance of RF-PFC as the disease activity subsided. In rare instances we have had opportunity to observe a negative test for RF-PFC during quiescence become positive during an exacerbation.
RF-PFC have not always been identified in the peripheral blood in exacerbating joint disease. On the other hand, they have uniformly been identified in patients with necrotizing vasculitis (Table V) . In patients with necrotizing vasculitis, active joint disease is often clinically insignificant. A 71-yr-old patient with "burned out" joint disease is of special interest (Fig. 6) . Although this patient had had no specifically active joint disease for several years, she continued to have a high sedimentation rate, nail fold thrombi, diffuse musculoskeletal pain and profound weakness, RF-PFC in her peripheral blood and BM, and a markedly increased catabolism of her IgG.' When steroids, which she had "Only 33 of the 67 patients in the first series provided usable information, because the laboratory data sought were not obtained simultaneously with the RF-PFC. ' received for many years, were briefly decreased during the early observation period in our Clinical Research Center, she developed diffuse erythema marginata, especially over the back. Serial BM and peripheral blood evaluations were carried out (Fig. 6 ). Three features are evident: (a) the BM regularly exhibited more RF-PFC/10' lymphocytes than did the peripheral blood; Types of extra-articular rheumatoid disease other than necrotizing vasulitis may also be correlated with RF-PFC in the peripheral blood. We have recently observed a patient with "burned out" arthritis, but continued active formation of subcutaneous nodules, Felty's syndrome, a severe bilateral sensory polyneuropathy, a very high sedimentation rate, and a markedly increased catabolic decay of her own IgG.' Numerous RF-PFC persistently have been present in her blood.
DISCUSS ION
In the RF-PFC assay reported herein, direct hemolysis of sensitized SRC was produced in agar. This is assumed to be due to cells producing complement-fixing IgM-RF (8, 22) . Reduced and alkylated IgG hemolysin was used as the SRC sensitizer, since reduced and alkylated hemolysin has no ability by itself to fix complement to the SRC, but remains reactive with RF (9, 23) . The plaque assay system is specific for RF. It is inhibited by as little as 2-10 Ag of human or rabbit IgG in the agar, less so by bovine IgG, and not at all by 10% FBS.
It was of some interest that the order of the abilities of the various species of IgG to inhibit RF-PFC was different from that by which they inhibited the RF in the blood serums (SCAT). Human IgG was most efficient in the RF-PFC, while tabbit IgG was most efficient in the SCAT. This difference brings up the possi-bility that the RF that we have traditionally studied in the peripheral blood serum is not properly representative of RF as it is made, but rather it is the residual of the original RF after complexing with interstitial and circulating IgG, precipitation, phagocytosis, or other fate in the tissues. This is obviously an important area for further study.
We have previously speculated that polyclonal IgMI-RF may be composed of a spectrum of monoclonal RF molecules, the majority of which are noncomplement fixing, a minority being complement fixing (9) . Since noncomplenment-fixing IgMI-RF would not be detected in our direct hemolytic plaque assay system, we have used a rabbit anti-IgM serum in an attempt to bring out such postulated nonhemolytic RF in an indirect assay. This attempt has been unsuccessful. We used for this attempt, however, an IgG anti-IgM, and the IgG of the antiserum was in sufficient concentration to cause by itself some inhibition of the system such as that illustrated in Fig. 1 The BM has long been known to be a source of lymphocytes capable of repopulating thymic, splenic, and nodal organs (24) . It is also an organ capable of considerable antibody (25) and gamma globulin (26) production. We have previously reported in systemic lupus erythematosus anti-DNA PFC in high numbers in the BM of patients with acute exacerbations (27) of that disease.
The higher numbers of RF-PFC in joint fluids than in simultaneously obtained peripheral bloods may mean local RF-PFC production in the joints; but it also may mean local entrapment of RF-PFC from the circulating blood. In a study of autoimmune thyroiditis in the rabbit, Clinton and Weigle (28) 
